Matthew Lyne sold $1.4M of VAL
SVP - CCO at Valaris Ltd. 26,000 shares at an average of $55.77, traded Sep 30, 2024, filed Sep 30, 2024.
Score components
- +15RoleOfficer
- +25Trade size$1.4M at market
- +20Share of holdings soldSold 52% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -12.5%, 3m -23.1%, 6m -29.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000314808-24-000146, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 30, 2024 | SOpen-market sale Common Shares | -26,000 | $55.77 | $1.4M | 24,388 | Sep 30, 2024 |
Related signals
Other insiders at Valaris Ltd and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 55Moderate | VALsell Valaris Ltd | Gilles Luca SVP - COO | $1.7M 35,000 shares | -30% | |
| 38Weak | VALbuy Valaris Ltd | Anton Dibowitz President & CEO | $254k 7,500 shares | +3% | |
| 34Weak | VALsell Valaris Ltd | Christopher T Weber SVP - CFO | $198k 4,000 shares | -7% | |
| 58Moderate | Valaris Ltd | Gilles Luca SVP - COO | $1.7M 30,000 shares | -22% | |
| 66Notable | Valaris Ltd | Davor Vukadin SVP & General Counsel | $872k 15,403 shares | -54% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.